公开(公告)号：US20230346975A1

公开(公告)日：2023-11-02

申请号：US18247800

申请日：2021-10-05

Applicant: The Johns Hopkins University ,  George Mason University

Inventor： Yun Chen ,  Stavros Gaitanaros ,  Wei-Hung Jung ,  Enze Chen ,  Remi Veneziano

IPC: A61K47/69 ,  C12N15/117 ,  A61K47/54

CPC classification number: A61K47/6957 ,  C12N15/117 ,  A61K47/549 ,  A61K47/6927 ,  A61K47/6903 ,  C12N2310/17

Abstract: Described are implantable devices comprising DNA nanostructures comprising a cell ligand at a proximal end tethered to an implantable substrate at a distal end for delivery of CpG oligodeoxynucleotides to cancer cells and methods of use and systems thereof.

公开(公告)号：US20230338579A1

公开(公告)日：2023-10-26

申请号：US17930345

申请日：2022-09-07

Applicant: CureVac SE

Inventor： Mariola FOTIN-MLECZEK ,  Aleksandra KOWALCZYK ,  Regina HEIDENREICH ,  Patrick BAUMHOF ,  Jochen PROBST ,  Karl-Josef KALLEN

IPC: A61K48/00 ,  A61K38/19 ,  A61K38/20 ,  A61K39/395 ,  C07K16/28 ,  C07K16/34 ,  A61K39/12 ,  A61K31/7105 ,  A61K31/713 ,  C12N15/117 ,  A61K9/00 ,  A61K38/17 ,  A61K39/145 ,  A61K39/39 ,  A61K45/06 ,  C07K16/30 ,  C12N7/00

CPC classification number: A61K48/005 ,  A61K38/19 ,  A61K38/208 ,  A61K39/3955 ,  C07K16/2818 ,  C07K16/2896 ,  C07K16/34 ,  A61K39/12 ,  A61K31/7105 ,  A61K31/713 ,  A61K48/0025 ,  A61K38/191 ,  C12N15/117 ,  A61K9/0019 ,  A61K38/177 ,  A61K38/1774 ,  A61K39/145 ,  A61K39/39 ,  A61K39/39558 ,  A61K45/06 ,  A61K48/0041 ,  C07K16/2878 ,  C07K16/30 ,  C12N7/00 ,  A61K2039/55522

Abstract: The present invention relates to RNA containing compositions for use in the treatment or prophylaxis of tumor and/or cancer diseases, to a pharmaceutical composition, to a kit and to uses of the RNA containing compositions for the treatment or prophylaxis of tumor and/or cancer diseases.

公开(公告)号：US11773395B1

公开(公告)日：2023-10-03

申请号：US18065243

申请日：2022-12-13

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Andrew Geall

IPC: C12N15/117 ,  C12N15/86 ,  A61K39/155 ,  A61K39/39 ,  A61K39/12 ,  A61P31/12 ,  A61P37/04 ,  A61K48/00 ,  A61K39/00

CPC classification number: C12N15/117 ,  A61K39/12 ,  A61K39/155 ,  A61K39/39 ,  A61K48/0041 ,  A61K48/0083 ,  A61P31/12 ,  A61P37/04 ,  C12N15/86 ,  A61K2039/53 ,  A61K2039/552 ,  A61K2039/55555 ,  A61K2039/55566 ,  C12N2760/18534 ,  C12N2770/36143 ,  C12N2820/60

Abstract: RNA encoding an immunogen is delivered to a large mammal at a dose of between 2 μg and 100 μg. Thus the invention provides a method of raising an immune response in a large mammal, comprising administering to the mammal a dose of between 2 μg and 100 μg of immunogen-encoding RNA. Similarly, RNA encoding an immunogen can be delivered to a large mammal at a dose of 3 ng/kg to 150 ng/kg. The delivered RNA can elicit an immune response in the large mammal.

公开(公告)号：US20230193288A1

公开(公告)日：2023-06-22

申请号：US18048390

申请日：2022-10-20

Applicant: Nutcracker Therapeutics, Inc.

Inventor： Samuel DEUTSCH ,  Daniel FRIMANNSSON ,  Nicole FAY ,  Colin McKINLAY

IPC: C12N15/117 ,  A61K45/06 ,  C07K16/28 ,  A61K9/14 ,  A61P35/00

CPC classification number: C12N15/117 ,  A61K45/06 ,  C07K16/2818 ,  A61K9/145 ,  A61P35/00

Abstract: Provided herein are examples of mRNA treatment nanoparticles and methods of using them to treat a patient. An mRNA treatment nanoparticle may include one or more mRNAs encoding a tumor-specific antigen and an immunomodulatory agent; and a delivery vehicle molecule encapsulating the one or more mRNAs.

公开(公告)号：US20230095192A1

公开(公告)日：2023-03-30

申请号：US17759210

申请日：2021-03-01

Applicant: University of Washington

Inventor： Daniel Brewster STETSON ,  Katelyn BURLEIGH ,  Emily SCHUTSKY

IPC: C12N15/117 ,  A61P37/02

Abstract: Polynucleotide constructs are disclosed, that are potent activators of a STING-independent DNA sensing pathway (SIDSP), in which the DNA damage response protein DNA-PK is the sensor of the SIDSP, along with tire heat shock protein HSPA8 as a unique SIDSP target. The polynucleotide constructs of the disclosure are also potent activators of the cGAS-STING DNA sensing pathway. These pathways arm key components of the innate immune response that is important for antiviral immunity, contributes to specific autoimmune diseases, and mediate important aspects of antitumor immunity.

公开(公告)号：US20230072079A1

公开(公告)日：2023-03-09

申请号：US17786631

申请日：2020-12-18

Applicant: Evaxion Biotech A/S

Inventor： Birgitte Rønø ,  Jens Kringelum ,  Anders Bundgård Sørensen ,  Thomas Trolle ,  Stine Friis

IPC: A61K39/00 ,  C12N15/117 ,  C12N15/85 ,  A61K39/39 ,  A61P35/00

Abstract: Products and methods for DNA vaccination targeting cancer. A method for anti-cancer vaccination using a plasmid-based vaccine comprising regions encoding neo-epitopes.

公开(公告)号：US20230052009A1

公开(公告)日：2023-02-16

申请号：US17840967

申请日：2022-06-15

Applicant: The Trustees of the University of Pennsylvania

Inventor： Katalin Kariko ,  Drew Weissman

IPC: A61K48/00 ,  C07K14/47 ,  C07K14/505 ,  C12N15/117 ,  C12N15/67 ,  C12N5/071 ,  C12N5/074 ,  C07H21/02 ,  C12Q1/68 ,  C12N15/85 ,  A61K38/17 ,  A61K38/18 ,  A61K38/50

Abstract: This invention provides RNA, oligoribonucleotide, and polyribonucleotide molecules comprising pseudouridine or a modified nucleoside, gene therapy vectors comprising same, methods of synthesizing same, and methods for gene replacement, gene therapy, gene transcription silencing, and the delivery of therapeutic proteins to tissue in vivo, comprising the molecules. The present invention also provides methods of reducing the immunogenicity of RNA, oligoribonucleotide, and polyribonucleotide molecules.

公开(公告)号：US20220401555A1

公开(公告)日：2022-12-22

申请号：US17809680

申请日：2022-06-29

Applicant: CureVac AG

Inventor： Thomas KRAMPS ,  Söhnke VOSS ,  Jochen PROBST ,  Ingmar HOERR

IPC: A61K39/39 ,  C07H21/00 ,  C12N15/117

Abstract: The present invention relates to nucleic acids of the general formula (I): (NuGlXmGnNv)a and derivatives thereof as an immunostimulating agent/adjuvant and to compositions containing same, optionally comprising an additional adjuvant. The present invention furthermore relates to a pharmaceutical composition or to a vaccine, each containing nucleic acids of formula (I) above and/or derivatives thereof as an immunostimulating agent, and optionally at least one additional pharmaceutically active component, e.g. an antigenic agent. The present invention relates likewise to the use of the pharmaceutical composition or of the vaccine for the treatment of cancer diseases, infectious diseases, allergies and autoimmune diseases etc. Likewise, the present invention includes the use of nucleic acids of the general formula (I): (NuGlXmGnNv)a and/or derivatives thereof for the preparation of a pharmaceutical composition for the treatment of such diseases.

公开(公告)号：US20220364095A1

公开(公告)日：2022-11-17

申请号：US17743422

申请日：2022-05-12

Applicant: NORTHWESTERN UNIVERSITY

Inventor： Chad A. Mirkin ,  Jasper Wilson Dittmar

IPC: C12N15/117 ,  A61K39/39

Abstract: The disclosure is generally related to spherical nucleic acids (SNAs), structures comprising a nanoparticle core surrounded by a shell of oligonucleotides. In some aspects the disclosure provides a spherical nucleic acid (SNA) comprising: (a) a nanoparticle core; and (b) a shell of oligonucleotides attached to the nanoparticle core, wherein one or more oligonucleotides in the shell of oligonucleotides is attached to the nanoparticle core through a hydrophobic anchor comprising one or more dodecane (C12) subunits. Methods of making and using the SNAs are also provided herein.

公开(公告)号：US20220267771A1

公开(公告)日：2022-08-25

申请号：US17616413

申请日：2020-06-02

Applicant: Shionogi & Co., Ltd.

Inventor： Tetsuya TANINO ,  Mitsuaki SEKIGUCHI ,  Shunsuke OCHI ,  Nobuaki FUKUI

IPC: C12N15/117 ,  C07F9/572

Abstract: Provided are production methods capable of controlling quality of a bifurcated lipid-linked oligonucleotide, and intermediates which is useful for the production method, has good stability, and is easy to manage and analyze. Specifically, it is a method for producing a bifurcated lipid-linked oligonucleotide including a step of reacting a compound of formula (II): wherein Pro1 to Pro4 are each independently a protecting group; Pro1 and Pro2 or Pro3 and Pro4 may be taken together to form a protecting group; m, n and p are each independently an integer of 0 to 5; and Y is a group of a formula: —P(OC2H4CN)(N(i-Pr)2), or the like, with an oligonucleotide.